Showing 5571-5580 of 7689 results for "".
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Lecture Updates on Abrocitinib, Povorcitinib for PNhttps://practicaldermatology.com/news/lecture-updates-abrocitinib-povorcitinib-pn/2468486/Dr. Shawn Kwatra gets goosebumps when he thinks about having two approved biologics for prurigo nodularis, (PN) he said during a session at the 44th Annual Fall Clinical Dermatology Conference. “I have to pinch myself,” Dr. Kwatra said during “Making the Connection Between Prurigo Nodulari
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<
- Atopic Dermatitis Linked to Peripheral Vascular Diseasehttps://practicaldermatology.com/news/atopic-dermatitis-linked-peripheral-vascular-disease/2468444/People with atopic dermatitis (AD) are almost twice as likely to develop peripheral vascular disease (PVD), Yale School of Medicine researchers found in a new study. “Associated between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Pro
- READY-4: Sustained and Safety Efficacy of RelabotulinumtoxinAhttps://practicaldermatology.com/news/ready-4-sustained-and-safety-efficacy-relabotulinumtoxina/2468443/New results from the phase III READY-4 trial presented at the 2024 ASDS Annual Meeting demonstrate the long-term safety and sustained efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) for the treatment of moderate-to-severe frown lines and crow’s feet. The multicenter, open-label REA
- New Eczema Relief Balm Available From Avènehttps://practicaldermatology.com/news/new-eczema-relief-balm-available-avene/2468441/French skincare brand Avène introduced XeraCalm Eczema Calming Relief Balm and Cicalfate+ Intensive Skin Restoration Serum, two new innovations that feature the company’s mineral-rich Thermal Spring Water. “These breakthrough formulations are at the heart of how Eau Thermale Avène cares fo
- Botox Approved for Platysma Bandshttps://practicaldermatology.com/news/botox-approved-platysma-bands/2468436/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a press release, B